Open access · US-GOV
via ClinicalTrials.gov Clinical trial
An Open-Label Extension Study Investigating the Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease
Authors not listed
NeuroEM Therapeutics, Inc. · 2019
Abstract
This is an extension of EM 1000-1 wherein subjects who participated in the original study have been given the opportunity to participate in a 4-month extension of TEMT. Seven of the eight subjects in the original EM 1000-1 agreed to participate in this study extension. The time between completion of the initial study's 2-month treatment period and the beginning of this extension study's 4-month treatment period will range from 4 months to 13 months (due to staggered start of treatment in the initial study). This extension study's primary objective is to determine the effects of a follow-up treatment period of 4-months on performance of Alzheimer's Disease (AD) subjects in the same comprehensive array of cognitive tasks they performed in the initial 2-month treatment study. Baseline cognitive performance will be compared to performance at both 2-months into treatment and at the end of the 4-month treatment period. Secondary objectives include analysis of blood and CSF for AD markers and evaluation of safety throughout the treatment period.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-14 MST
Cite this
APA
Anonymous. (2019). An Open-Label Extension Study Investigating the Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease. <em>NeuroEM Therapeutics, Inc.</em>. https://clinicaltrials.gov/study/NCT03927040
Vancouver
Anonymous. An Open-Label Extension Study Investigating the Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease. NeuroEM Therapeutics, Inc.. 2019.
BibTeX
@misc{anon2019AnOpen,
title = {An Open-Label Extension Study Investigating the Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease},
author = {Anonymous},
journal = {NeuroEM Therapeutics, Inc.},
year = {2019},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
University of California, Davis 2022
Open access · US-GOV
Proof of Mechanism Study of Senicapoc in Mild or Prodromal Alzheimer's Disease
AbbVie (prior sponsor, Abbott) 2009
Open access · US-GOV
A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease
Gerencia de Atención Primaria, Madrid 2014
Open access · US-GOV
Cardiovascular Risk in People Older Than 55 Years and Cognitive Performance at 5 Years: an Estimation Model Based on Spanish Population. NEDICES-2-RISK Study.
Riphah International University 2024
Open access · US-GOV
The Effects of Brain Training Games on Cognitive Function and Quality of Life Among Older Adults With Mild Cognitive Impairment
Beijing Friendship Hospital 2016
Open access · US-GOV
Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease: A Multi-center Single-arm Study in China
Merck Sharp & Dohme LLC 2010
Open access · US-GOV